Search

Displaying results 2811 - 2820 of 10000 in total
  1. Drug

    Tenocyclidine

    go.drugbank.com/drugs/DB01520
    IllicitInvestigational

    It is more potent than phencyclidine and hence, this drug was classified under the schedule 1 in 1970.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Procarbazine

    go.drugbank.com/drugs/DB01168
    ApprovedInvestigational

    An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.

    Synonyms: N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine, N-Isopropyl-α-(2-methylhydrazino)-p-toluamide
  3. Drug

    Iroxanadine

    go.drugbank.com/drugs/DB05444
    Experimental

    It induces phosphorylation of p38 SAPK, which plays an important role in EC homeostasis. endothelial cell (EC). … EC function plays a central role in vascular diseases (e.g. atherosclerosis, restenosis, diabetic angiopathies, microvascular angina, peripheral arterial disease).

  4. Drug

    Cinnarizine

    go.drugbank.com/drugs/DB00568
    ApprovedInvestigational

    First synthesized by Janssen Pharmaceuticals in 1955, cinnarizine is an anti-histaminic drug mainly used for the control of vestibular disorders and motion sickness. … Combination use of cinnarizine with other nootropics, such as [piracetam] resulted in enhanced effect of boosting brain oxygen supply.

    Products: CN - 25
  5. Drug

    Peramivir

    go.drugbank.com/drugs/DB06614
    ApprovedInvestigational

    Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. … Being an influenza virus neuraminidase inhibitor, peramivir works by preventing new viruses from emerging from infected cells.

  6. Drug

    Ganaxolone

    go.drugbank.com/drugs/DB05087
    ApprovedInvestigational

    [L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636] … [L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment

  7. Drug

    Plasminogen

    go.drugbank.com/drugs/DB16701
    ApprovedInvestigational

    [L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions to form on the mucous membranes of patients, providing an unmet medical need for patients with … [L34635] In June 2021, the FDA approved a plasma-derived plasminogen (Ryplazim, human plasminogen-tvmh)[L34620] for the treatment of type 1 plasminogen deficiency (hypoplasminogenemia).

  8. Drug

    Retifanlimab

    go.drugbank.com/drugs/DB15766
    ApprovedInvestigational

    On October 2021, Incyte Biosciences withdrew its application for a marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal. … [L45603,L45613] The use of retifanlimab in combination with other oncology drugs for the treatment of metastatic gastroesophageal adenocarcinoma has also been evaluated.[A258383,A258388]

  9. Drug

    Denileukin diftitox

    go.drugbank.com/drugs/DB00004
    ApprovedInvestigational

    on August 8, 2024. … approved to treat a human disease in the US.

    Synonyms: N-MET-187-HIS-388-ALA-1-388-TOXIN (CORYNEBACTERIUM DIPHTHERIAE C7) WITH 1-133-INTERLEUKIN 2, N-L-METHIONYL-387-L-HISTIDINE-388-L-ALANINE-1-388-TOXIN (CORYNEBACTERIUM DIPHTHERIAE STRAIN C7) (388->2') PROTEIN WITH 2-133-INTERLEUKIN 2 (HUMAN CLONE PTIL2-21A)
  10. Drug

    REN-850

    go.drugbank.com/drugs/DB05912
    Experimental

    REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.